Company news
ImmuPharma plc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Extension of warrants in Incanthera plc
August 21, 2023
Directorate Change
August 11, 2023
Lupuzor Update
June 19, 2023
IMM RNS Posting of RA and Notice of AGM 30 June 23
June 6, 2023
Positive Pre-IND meeting with FDA
May 18, 2023
Lupozor Update - FDA confirms Type-C meeting date
April 19, 2023
CIDP P140 Clinical Program Update
April 12, 2023
LupuzorT Update
March 27, 2023
Price Monitoring Extension
March 9, 2023
Collaboration with Orano on ImmuPharma Peptide
March 6, 2023
TR-1: Notification of major holdings
January 27, 2023
Second Price Monitoring Extn
January 4, 2023
Grant of Options
December 22, 2022
Company Secretary Change
October 7, 2022
Interim Results or the 6mths Ended 30 June 2022
September 30, 2022
Written Response received from the FDA
September 14, 2022
Exercise of Options
September 7, 2022
FDA response for Type C Meeting - update
August 31, 2022
TR-1 Notification of major holdings
August 17, 2022
Total Voting Rights
August 16, 2022
Result of Broker Option / PDMR Dealings
August 11, 2022
Investor Presentation - Investor Meet Company
August 4, 2022
Subscription/Placing to raise £1.1m; Broker Option
August 3, 2022
Initiation of Research
July 11, 2022
Confirmed FDA response date for Type C Meeting
July 7, 2022
Admission of new ordinary shares of £0.01
June 28, 2022
Update on Lupuzor
June 27, 2022
Finals results for y/e 31 December 2021
May 25, 2022
UPDATE on LUPUZORT PROGRESS to PHASE 3 with AVION
May 4, 2022
UPDATE on P140 (LUPUZORT) clinical progress
April 13, 2022
Lupuzor update
February 7, 2022
Subscriptions and Placing to raise £3.55 million
December 20, 2021
Collaboration with Imperial College London
November 29, 2021
Euronext Delisting
October 1, 2021
Prof. Sylviane Muller awarded 'Legion d'honneur'
September 30, 2021
Interim Results for the 6months ended 30 June 2021
September 29, 2021
Director/PDMR Shareholding
August 24, 2021
Notification of Major Holdings
August 17, 2021
FDA approves the LupzuorT PK study
August 12, 2021
Board Changes
July 30, 2021
Board Appointment
July 16, 2021
2021 Result of annual general meeting -replacement
June 28, 2021
Update: LupzuorT PK study
June 24, 2021
Notice of AGM and posting of Report & Accounts
June 2, 2021
Director Retirement
May 24, 2021
Update- scheduled Phase 3 trials in lupus patients
February 9, 2021
IMM to present at biotech showcase digital 2021
December 2, 2020
Total Share Capital Notification
November 30, 2020
Grant of Share Options & PDMR dealing
November 26, 2020
Conversion of Convertible Security
November 24, 2020
Calls
Decks
- Investor Presentation (April 2020)
Investor deck · 15 slides · April 2020